GlassScriptPhysician profile
Chandan D Lad
NPI 1164409025
$22,289.62
in general payments reported to CMS, 2019-2025
55 companies · $2,325 in 2025
The $2,325 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,009 · 2020: $2,733 · 2021: $3,969 · 2022: $3,874 · 2023: $3,015 · 2024: $3,364 · 2025: $2,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,704.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,715.57 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,335.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $2,053.28 | 2019-2025 | |
| Lilly USA, LLC | $1,819.76 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,596.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,199.48 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $948.89 | 2022-2025 | |
| Abbott Laboratories | $785.70 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $674.14 | 2019-2025 | Evenity, Prolia, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $649.82 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $604.89 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $604.17 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $584.06 | 2019-2022 | |
| Axsome Therapeutics, INC. | $578.05 | 2022-2025 | Auvelity, Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $523.45 | 2019-2025 | Jardiance, Ofev |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandan Lad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.